Evolution of Renal Cell Carcinoma
- PMID: 32007485
- DOI: 10.1016/j.euf.2019.12.005
Evolution of Renal Cell Carcinoma
Abstract
A diverse range of clinical phenotypes are observed in clear-cell renal cell carcinoma (ccRCC) with resultant therapeutic implications. Molecular characterisation underpinning the diversity observed has been qualified, where the near ubiquitous loss of the short arm of chromosome 3 precedes distinct evolutionary trajectories involving different sequences and combinations of genetic events. Primary tumours are characterised by varying degrees of intratumoural heterogeneity and chromosomal complexity associated with distinct metastatic phenotypes. An evolutionary understanding reconciles the diverse clinical phenotypes observed in metastatic ccRCC and has the potential to impact patient management. PATIENT SUMMARY: Re-tracing the evolutionary paths taken by clear-cell kidney cancer through analyses at the gene level gives an insight into genetic changes that are correlated to metastatic potential. This may provide a framework to guide therapeutic interventions, especially in identifying candidates for surgical intervention.
Keywords: Chromosomal complexity; Intratumoural heterogeneity; Linear, branched, and punctuated evolution.
Crown Copyright © 2020. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.Cell. 2018 Apr 19;173(3):595-610.e11. doi: 10.1016/j.cell.2018.03.043. Epub 2018 Apr 12. Cell. 2018. PMID: 29656894 Free PMC article.
-
Tracing Clonal Dynamics Reveals that Two- and Three-dimensional Patient-derived Cell Models Capture Tumor Heterogeneity of Clear Cell Renal Cell Carcinoma.Eur Urol Focus. 2021 Jan;7(1):152-162. doi: 10.1016/j.euf.2019.06.009. Epub 2019 Jun 29. Eur Urol Focus. 2021. PMID: 31266731
-
Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.EBioMedicine. 2020 Jan;51:102526. doi: 10.1016/j.ebiom.2019.10.052. Epub 2019 Dec 16. EBioMedicine. 2020. PMID: 31859241 Free PMC article.
-
Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications.Cancer Lett. 2013 Dec 1;341(2):111-26. doi: 10.1016/j.canlet.2013.08.006. Epub 2013 Aug 7. Cancer Lett. 2013. PMID: 23933176 Review.
-
[Intratumoral heterogeneity in renal cell carcinoma. Molecular basis and translational implications].Urologe A. 2015 Jun;54(6):800-3. doi: 10.1007/s00120-015-3800-9. Urologe A. 2015. PMID: 25758237 Review. German.
Cited by
-
Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis.J Cancer. 2020 Oct 18;11(24):7202-7208. doi: 10.7150/jca.48062. eCollection 2020. J Cancer. 2020. PMID: 33193883 Free PMC article.
-
TRIM26 inhibits clear cell renal cell carcinoma progression through destabilizing ETK and thus inactivation of AKT/mTOR signaling.J Transl Med. 2024 May 21;22(1):481. doi: 10.1186/s12967-024-05273-w. J Transl Med. 2024. PMID: 38773612 Free PMC article.
-
The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity.Cancers (Basel). 2021 May 24;13(11):2574. doi: 10.3390/cancers13112574. Cancers (Basel). 2021. PMID: 34073906 Free PMC article.
-
Clear Cell Renal Cell Carcinoma: A Test Bench for Investigating Tumor Complexity.Cancers (Basel). 2024 Feb 19;16(4):829. doi: 10.3390/cancers16040829. Cancers (Basel). 2024. PMID: 38398220 Free PMC article.
-
Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model.Biol Open. 2021 Apr 15;10(4):bio058566. doi: 10.1242/bio.058566. Epub 2021 Apr 20. Biol Open. 2021. PMID: 33913471 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical